epirubicin / Generic mfg. - LARVOL DELTA

A CASE OF LATE-ONSET NEPHROTIC-RANGE PROTEINURIA CAUSED BY AN ANTI-ANGIOGENIC THERAPY FOR METASTATIC BREAST CANCER (ISN-WCN 2026) - "After changing to epirubicin/cyclophosphamide (EC) regimen, the patient's condition had been rather stable after 6 courses of EC therapy, when nausea and general malaise developed and worsened. Then, the regimen was changed to weekly paclitaxel plus bevacizumab (PTX/BEV) therapy...Because it was considered Grade 3 adverse events due to anti-angiogenic therapy, BEV was discontinued and the patient was followed with azilsartan and dapagliflozin...Conclusion The adverse events due to anti-angiogenic therapy are reported to be high, with proteinuria (∼10% to 60%) and hypertension being most prevalent. The interval between initiation of the therapy and the onset of proteinuria varies significantly (several weeks to ∼1 year), but the present case exhibited apparent proteinuria after 80 weeks of therapy. It is important to continuously follow up with close attention to renal function and urinalysis during and after anti-angiogenic therapy, even when the patient has remained..."

Clinical • Metastases • Breast Cancer • Hypertension • Nephrology • Oncology • Renal Disease • Solid Tumor

BRCA2 Reversion Mutation after Neoadjuvant Dose-Dense EC and Dose-Dense Paclitaxel in Triple-Negative Breast Cancer: A Case Report and Literature Review. (PubMed, Surg Case Rep) - "This case suggests that a BRCA2 reversion mutation can arise early, even before PARPi or platinum exposure. Serial monitoring of BRCA status may help predict therapeutic resistance in patients with germline BRCA-mutated breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA2

Biomimic colloidal self-assembly of epirubicin/ferric ion multi-enzyme delivery for synergistic photothermal therapy of metastatic triple-negative breast cancer. (PubMed, Colloids Surf B Biointerfaces) - "PEF NDs had no detrimental effects on vital organs (heart, kidney, liver, lung, or spleen), indicating acceptable in vivo biosafety. Self-assembled nanodrugs with simultaneous photothermal and anti-inflammatory properties have considerable clinical potential in the treatment of metastatic malignancies."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CAT • MMP9

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov) - P=N/A | N=43 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC) (ESMO 2024) - P2 | "Neo-CheckRay (NCT03875573) is the first prospective, international, phase 2, randomized trial investigating this treatment. Eligible patients (pts) with newly diagnosed cT1c-3 (≥ 2 cm) cN0 or cT1c-3 (≥ 1.5 cm) cN1-3, grade 2 (Ki67 ≥ 15%) or grade 3, MammaPrint (MP) high risk, invasive ER+/HER2- BC were randomized 1:1:1 to arm 1: neo-adjuvant paclitaxel q1w x12 with SBRT at week 5 (3x8 Gy targeting the primary tumour, avoiding lymph nodes and normal breast tissue), followed by dose-dense epirubicin/cyclophosphamide q2w x4; arm 2: arm 1 + durva 1500mg q4w x5; and arm 3: arm 2 + ole 3000 mg q2w x4 then q4w x3. The addition of durva+/- ole numerically increases pCR and RCB 0/1 rates compared to NACT+SBRT. Final statistical analysis will be presented at the conference. Ongoing translational research will shed light on the mechanisms of response."

Clinical • Late-breaking abstract • P2 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial (SABCS 2025) - P3 | "This study aimed to evaluate the efficacy and safety of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without carboplatin as adjuvant therapy for patients with high-risk early-stage TNBC. This open-label, randomized, phase 3 trial was conducted in China. The addition of carboplatin to adjuvant anthracycline/taxane-based chemotherapy significantly improves survival outcomes with manageable toxicity in patients with high-risk early-stage TNBC.Trial registration number: ClinicalTrials.gov (NCT04296175).Figure 1 Clinical outcomes. Kaplan-Meier plots show disease-free survival (A), recurrence-free survival (B), distant disease-free survival (C) and overall survival (D) for patients.Figure 2 Exploratory subgroup analyses for disease-free survival. HR, Hazard Ratio; CI, confidence interval."

Clinical • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

LESLIE: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - P2 | N=356 | Recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2031 ➔ Sep 2031 | Trial primary completion date: Mar 2028 ➔ Sep 2028

Enrollment open • Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov) - P3 | N=1800 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study (ESMO 2024) - P3 | "Here, we present the final OS results. Eligible pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to neoadjuvant pembro 200 mg Q3W or placebo (pbo), both given with 4 cycles of paclitaxel + carboplatin, then 4 cycles of doxorubicin or epirubicin + cyclophosphamide. Neoadjuvant pembro + chemo followed by adjuvant pembro showed a statistically significant and clinically meaningful improvement in OS compared with neoadjuvant chemotherapy alone in pts with high-risk early-stage TNBC."

Clinical • IO biomarker • Late-breaking abstract • P3 data • Oncology • Triple Negative Breast Cancer • NODAL • PD-L1

Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial (SABCS 2025) - P3 | "Taxanes consisted of either weekly paclitaxel for 12 doses or docetaxel every 3 weeks for 4 cycles. Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. While additional carboplatin treatment was associated with increased hematologic toxicity, no new safety signals emerged."

Clinical • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Effect of a Porous Glass-Membrane Emulsification Method on Radiological Response in Epirubicin–Lipiodol cTACE for HCC (APASL 2026) - No abstract available

Hepatocellular Cancer

Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Hong Wu

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (clinicaltrials.gov) - P3 | N=1240 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PD-L1

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (clinicaltrials.gov) - P3 | N=1140 | Recruiting | Sponsor: Merck Sharp & Dohme Corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PD-L1

Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT). (ASCO-GU 2026) - " This retrospective cohort study using SEER-Medicare data (1/1/2007-12/31/2022) included treatment-naïve patients ≥65 years old with HR-NMIBC with PAP (T1 disease or high-grade Ta) or CIS (Tis staging or diagnosis code), who received ≥1 instillation of BCG (BCG cohort) or other IVT (IVT cohort; mitomycin, gemcitabine, valrubicin, docetaxel, epirubicin) as 1L treatment...Recurrence was defined as reinitiation of the same therapy after a gap (BCG: ≥180-day gap; other IVT: ≥90-day gap), transurethral resection of bladder tumor (TURBT), biopsy, or initiation of a new treatment (i.e., alternative IVT, systemic chemotherapy, radiotherapy, cystectomy, immunotherapy [including pembrolizumab], hormonal therapy, or other antineoplastic therapy)... In this real-world study of Medicare-insured patients with HR-NMIBC with PAP or CIS, over 60% experienced recurrence within 12 months of initiating 1L BCG or IVT. While most BCG-treated patients received adequate induction, just..."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (clinicaltrials.gov) - P3 | N=1140 | Not yet recruiting | Sponsor: Merck Sharp & Dohme Corp.

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PD-L1

A clinical study of sac-TMT in people with breast cancer (MK-2870-032) (clinicaltrialsregister.eu) - P2/3 | N=565 | Recruiting | Sponsor: Merck Sharp & Dohme LLC

New P2/3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. (PubMed, BMJ) - P3 | "The addition of carboplatin to adjuvant anthracycline/taxane based chemotherapy significantly improved survival outcomes in patients with high risk, early stage, triple negative breast cancer, driven by reduction of early recurrence risk without new safety concerns."

Clinical • Journal • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Optical spectral fingerprinting for anthracycline detection in synthetic clinical biofluids (AACR 2026) - "To create chemical library diversity, multi-species SWCNT were dispersed with 12 unique ssDNAs and challenged with four anthracyclines: daunorubicin, doxorubicin, epirubicin, and idarubicin, at concentrations ranging from 0.1-100 μM. Future work will use these ssDNA-SWCNT species combinations to develop a noninvasive therapeutic drug monitoring tool to monitor accumulation at the tumor and in the heart during chemotherapy. We anticipate this work leading to a tool to improve tolerance for anthracycline chemotherapy by establishing personalized pharmacological treatment windows."

Clinical • Oncology

Against the Clock: Early Chemotherapy During VA ECMO in Cardiac DLBCL (SCCM 2026) - "On day 12 of VA-ECMO, the patient was started on his first cycle of chemotherapy with rituximab, cyclophosphamide, epirubicin, and vincristine (R-CHO). Our case shows that the initiation of chemotherapy with concurrent ECMO is beneficial in patients with unstable hemodynamics. However, chemotherapy should be carefully designed and personalized to minimize the risk of infection and hemorrhage."

B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. (PubMed, Breast Care (Basel)) - P2/3 | "Patients with c/pN2-3 or G3 with Ki67 >40% were randomized directly to CTx subtrial evaluating (neo)adjuvant paclitaxel vs. nab-paclitaxel, followed by epirubicin + cyclophosphamide and ET...Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

COMPARATIVE EFFECTIVENESS OF CONTINUOUS INFUSION, DEXRAZOXANE, EPIRUBICIN, AND LIPOSOMAL DOXORUBICIN FOR PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY: A NETWORK META-ANALYSIS (ACC 2026) - "Preventive strategies include continuous infusion (CIV), dexrazoxane, epirubicin, and pegylated liposomal doxorubicin (PLD), but they have been tested only in isolation. PLD, dexrazoxane, and CIV each reduced anthracycline cardiotoxicity by ~75-80% versus bolus doxorubicin, while epirubicin provided moderate benefit, with efficacy preserved across all strategies. This unified comparative ranking offers a robust evidence base for cardio-oncology guidelines and survivorship care."

HEOR • Retrospective data • Breast Cancer • Cardiovascular • Hematological Malignancies • Mucositis • Sarcoma • Solid Tumor

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. (PubMed, J Clin Oncol) - "Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged."

Journal • P3 data • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

In vivo dynamic nuclear polarization magnetic resonance imaging reveals cardiac mitochondrial redox imbalance as an early indicator of heart failure. (PubMed, Redox Biol) - "We applied in vivo dynamic nuclear polarization magnetic resonance imaging (DNP-MRI) to a mouse model of doxorubicin (DOX)-induced heart failure to validate its utility...However, no significant change was detected in epirubicin-treated mice compared with control animals. Considering that DOX induces ROS production through redox cycling at mitochondrial ETC complex I, these results demonstrate that in vivo DNP-MRI enables noninvasive visualization of ETC-associated mitochondrial redox imbalance in the living heart immediately after the onset of cardiotoxic stress, even when ROS generation has just begun and conventional functional changes are unapparent. Therefore, in vivo DNP-MRI represents a powerful noninvasive modality for the early diagnosis of heart failure."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Circadian modulation of chemotherapy tolerance and inflammatory response in soft-tissue sarcoma: A real-world analysis of 55 patients (Sarcoma-RC 2026) - "Epirubicin-based chemotherapy remains a standard approach in advanced STS, often combined with ifosfamide, mesna, or gemcitabine. Legal entity responsible for the study Oncology Centre in Burgas LTD, Bulgaria. Funding Has not received any funding."

Clinical • Real-world • Real-world evidence • Breast Cancer • Colorectal Cancer • Mucositis • Sarcoma • Soft Tissue Sarcoma • Solid Tumor